A review of metformin in occurrence and prognosis of ovarian cancer
10.3969/j.issn.1006-2483.2020.01.023
- VernacularTitle:二甲双胍与卵巢癌发生及预后关系的研究
- Author:
Hanyuan WANG
1
,
2
;
Shuang ZHANG
1
,
2
;
Tingting GONG
3
;
Zhaoyan WEN
1
,
2
;
Qijun WU
1
,
2
Author Information
1. Department of Clinical Epidemiology, Shengjing Hospital, China Medical University, Shenyang 110004,China
2. Clinical Research Center，Shengjing Hospital of China Medical University，Shenyang 110004，China
3. Department of Obstetrics and Gynecology, Shengjing Hospital, China Medical University, Shenyang 110004,China
- Publication Type:Journal Article
- Keywords:
Metformin;
Ovarian cancer;
Incidence;
Prognosis
- From:
Journal of Public Health and Preventive Medicine
2020;31(1):100-104
- CountryChina
- Language:Chinese
-
Abstract:
Ovarian cancer is one of the most serious gynecological tumors in the world, and its mortality ranks first in gynecological malignancies. The study found that metformin is not only used as a first-line oral hypoglycemic agent for the treatment of type 2 diabetes, but also has a certain inhibitory effect on the occurrence and development of ovarian cancer. In recent years, domestic and foreign scholars have carried out experimental and epidemiological studies on the relationship between metformin and ovarian cancer. This review included 7 cohorts and 2 case-control studies on the incidence and prognosis of metformin and ovarian cancer. The results suggest that the use of metformin may improve the prognosis of ovarian cancer, however, due to the limited epidemiological studies of the disease, its relationship with ovarian cancer still needs further exploration.
